Werner J Pichler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6279881/publications.pdf

Version: 2024-02-01

183

all docs

174 10,647 56
papers citations h-index

citations h-index g-index

183 183 6504
docs citations times ranked citing authors

36028

97

#	Article	IF	CITATIONS
1	The important role of nonâ€covalent drugâ€protein interactions in drug hypersensitivity reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 404-415.	5.7	24
2	Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System. Frontiers in Allergy, 2022, 3, 827893.	2.8	6
3	Anaphylaxis to drugs: Overcoming mast cell unresponsiveness by fake antigens. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1340-1349.	5.7	12
4	The role of drug, dose, and the tolerance/intolerance of new drugs in multiple drug hypersensitivity syndrome. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1178-1187.	5.7	18
5	IgEâ€mediated chlorhexidine allergy—Crossâ€reactivity with other biguanide disinfectants. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3237-3247.	5.7	13
6	Drug-related relapses in drug reaction with eosinophilia and systemic symptoms (DRESS). Clinical and Translational Allergy, 2020, 10, 52.	3.2	15
7	Shared Genetic Risk Factors Across Carbamazepineâ€Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	4.7	52
8	Immune pathomechanism and classification of drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1457-1471.	5.7	131
9	Controversies in drug allergy: InÂvitro testing. Journal of Allergy and Clinical Immunology, 2019, 143, 56-65.	2.9	94
10	Drug hypersensitivity: We need to do more. Journal of Allergy and Clinical Immunology, 2018, 141, 89-91.	2.9	11
10	Drug hypersensitivity: We need to do more. Journal of Allergy and Clinical Immunology, 2018, 141, 89-91. Multiple Drug Hypersensitivity. International Archives of Allergy and Immunology, 2017, 172, 129-138.	2.9	67
11	Multiple Drug Hypersensitivity. International Archives of Allergy and Immunology, 2017, 172, 129-138. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pacific	2.1	67
11 12	Multiple Drug Hypersensitivity. International Archives of Allergy and Immunology, 2017, 172, 129-138. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pacific Allergy, 2016, 6, 77-89. Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. International	2.1	38
11 12 13	Multiple Drug Hypersensitivity. International Archives of Allergy and Immunology, 2017, 172, 129-138. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pacific Allergy, 2016, 6, 77-89. Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. International Archives of Allergy and Immunology, 2016, 171, 166-179. Flareâ€up reactions in severe drug hypersensitivity: infection or ongoing Tâ€cell hyperresponsiveness.	2.1 1.3 2.1	67 38 119
11 12 13	Multiple Drug Hypersensitivity. International Archives of Allergy and Immunology, 2017, 172, 129-138. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pacific Allergy, 2016, 6, 77-89. Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. International Archives of Allergy and Immunology, 2016, 171, 166-179. Flareâ€up reactions in severe drug hypersensitivity: infection or ongoing Tâ€eell hyperresponsiveness. Clinical Case Reports (discontinued), 2015, 3, 798-801. Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune	2.1 1.3 2.1 0.5	67 38 119 11
11 12 13 14	Multiple Drug Hypersensitivity. International Archives of Allergy and Immunology, 2017, 172, 129-138. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pacific Allergy, 2016, 6, 77-89. Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. International Archives of Allergy and Immunology, 2016, 171, 166-179. Flareâ€up reactions in severe drug hypersensitivity: infection or ongoing Tâ€cell hyperresponsiveness. Clinical Case Reports (discontinued), 2015, 3, 798-801. Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. International Archives of Allergy and Immunology, 2015, 168, 13-24. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.	2.1 1.3 2.1 0.5	67 38 119 11 71

#	Article	IF	CITATIONS
19	Enhancement of Drug-Specific Lymphocyte Proliferation Using CD25 ^{hi} -Depleted CD3 ⁺ Effector Cells. International Archives of Allergy and Immunology, 2014, 163, 198-205.	2.1	27
20	NSAID intolerance: it is not always what it seems. Clinical and Translational Allergy, 2014, 4, P7.	3.2	1
21	The involvement of specific t cells in the pathogenesis of metamizoleâ€induced agranulocytosis. Clinical and Translational Allergy, 2014, 4, P107.	3.2	3
22	T Cells Infiltrate the Liver and Kill Hepatocytes in HLA-Bâ^—57:01-Associated Floxacillin-Induced Liver Injury. American Journal of Pathology, 2014, 184, 1677-1682.	3.8	62
23	Drug Allergy. , 2014, , 1274-1295.		10
24	Abacavir Induced T Cell Reactivity from Drug NaÃ⁻ve Individuals Shares Features of Allo-Immune Responses. PLoS ONE, 2014, 9, e95339.	2.5	58
25	IgE-Mediated Allergies. , 2014, , 1-5.		0
26	Lymphocyte Transformation Test. , 2014, , 1-5.		2
27	Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. Dermatologica Sinica, 2013, 31, 181-190.	0.5	13
28	HLA-B*57:01+ abacavir-naive individuals have specific T cells but no patch test reactivity. Journal of Allergy and Clinical Immunology, 2013, 132, 756-758.	2.9	22
29	Allergy to sulfonamides. Journal of Allergy and Clinical Immunology, 2013, 131, 256-257.e5.	2.9	45
30	Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organization Journal, 2013, 6, 18.	3.5	55
31	HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin. Journal of Immunology, 2013, 190, 4956-4964.	0.8	98
32	In Memoriam - A Tribute to Alain L. de Weck. International Archives of Allergy and Immunology, 2013, 162, 97-98.	2.1	0
33	Sulfamethoxazole Induces a Switch Mechanism in T Cell Receptors Containing TCRV \hat{I}^2 20-1, Altering pHLA Recognition. PLoS ONE, 2013, 8, e76211.	2.5	55
34	Activating interactions of sulfanilamides with T cell receptors. Open Journal of Immunology, 2013, 03, 139-157.	0.2	19
35	Drug hypersensitivity., 2013,, 564-577.		0
36	Maintenance of Skills, Competencies, and Performance in Allergy and Clinical Immunology: Time to Lay the Foundation for a Universal Approach. World Allergy Organization Journal, 2012, 5, 45-51.	3.5	3

#	Article	IF	CITATIONS
37	Nonimmediate drug allergy: Diagnostic benefit of skin testing and practical approach. Journal of Allergy and Clinical Immunology, 2012, 129, 1170-1171.	2.9	13
38	Avidity determines <scp>T</scp> â€eell reactivity in abacavir hypersensitivity. European Journal of Immunology, 2012, 42, 1706-1716.	2.9	85
39	A World Allergy Organization International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity. World Allergy Organization Journal, 2011, 4, 257-270.	3.5	46
40	Preface. Journal of Allergy and Clinical Immunology, 2011, 127, S59.	2.9	7
41	Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2011, 127, 1543-1551.e3.	2.9	43
42	Individual IL-3 priming is crucial for consistent inÂvitro activation of donor basophils in patients with chronic urticaria. Journal of Allergy and Clinical Immunology, 2011, 128, 1227-1234.e5.	2.9	44
43	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	27.0	815
44	Educational case series: Mechanisms of drug allergy. Pediatric Allergy and Immunology, 2011, 22, 559-567.	2.6	21
45	Delayed drug hypersensitivity: models of Tâ€cell stimulation. British Journal of Clinical Pharmacology, 2011, 71, 701-707.	2.4	127
46	Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin. British Journal of Clinical Pharmacology, 2011, 71, 297-300.	2.4	14
47	Drug hypersensitivity: Flareâ€up reactions, crossâ€reactivity and multiple drug hypersensitivity. Journal of Dermatology, 2011, 38, 216-221.	1.2	61
48	T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cellular and Molecular Life Sciences, 2010, 67, 4171-4184.	5.4	131
49	Cross-Reactivity in Drug Hypersensitivity Reactions to Sulfasalazine and Sulfamethoxazole. International Archives of Allergy and Immunology, 2010, 153, 152-156.	2.1	52
50	Drug Antigenicity, Immunogenicity, and Costimulatory Signaling: Evidence for Formation of a Functional Antigen through Immune Cell Metabolism. Journal of Immunology, 2010, 185, 6448-6460.	0.8	53
51	The Complex Clinical Picture of Side Effects to Biologicals. Medical Clinics of North America, 2010, 94, 791-804.	2.5	40
52	Preface. Medical Clinics of North America, 2010, 94, xv-xvi.	2.5	2
53	Drug Hypersensitivity Reactions: Pathomechanism and Clinical Symptoms. Medical Clinics of North America, 2010, 94, 645-664.	2.5	100
54	Stimulation of human T cells with sulfonamides and sulfonamide metabolites. Journal of Allergy and Clinical Immunology, 2010, 125, 411-418.e4.	2.9	109

#	Article	IF	CITATIONS
55	Drug Hypersensitivity Reactions Involving Skin. Handbook of Experimental Pharmacology, 2010, , 29-55.	1.8	37
56	IgE-Mediated Anaphylaxis to Intraarticular Glucocorticoid Preparations. American Journal of Roentgenology, 2009, 193, W156-W157.	2.2	10
57	Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis. Circulation, 2009, 120, 391-399.	1.6	441
58	Preface. Immunology and Allergy Clinics of North America, 2009, 29, xv-xvi.	1.9	0
59	Mechanisms of Drug-Induced Allergy. Mayo Clinic Proceedings, 2009, 84, 268-272.	3.0	105
60	In Vitro Tests in Drug Hypersensitivity Diagnosis. Immunology and Allergy Clinics of North America, 2009, 29, 537-554.	1.9	41
61	Anaphylactoid Reactions to Radiopaque Contrast Dye–Reply–I. Mayo Clinic Proceedings, 2009, 84, 663.	3.0	O
62	Anaphylactoid Reactions to Radiopaque Contrast Dye–Reply–I. Mayo Clinic Proceedings, 2009, 84, 663.	3.0	0
63	Drug Allergy. , 2009, , 1205-1226.		10
64	Clinical Manifestations of Allergic Diseases: Drug Hypersensitivity., 2009,, 403-422.		1
65	Immunological Principles of Drug Hypersensitivity. , 2009, , 393-410.		O
66	Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance. Journal of Virology, 2008, 82, 3147-3153.	3.4	55
67	Design, Expression, and Processing of Epitomized Hepatitis C Virus-Encoded CTL Epitopes. Journal of Immunology, 2008, 181, 6361-6370.	0.8	17
68	The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors. World Allergy Organization Journal, 2008, 1, 96-102.	3.5	59
69	Drug hypersensitivity., 2008,, 709-724.		O
70	The p-i Concept: Evidence and Implications. , 2007, , 66-73.		5
71	Adverse Side Effects to Biological Agents. , 2007, , 151-165.		6
72	Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell Activation., 2007,, 168-189.		55

#	Article	IF	Citations
73	Drug-Induced Interstitial Nephritis. , 2007, , 295-305.		4
74	In vitro Tests of T-Cell-Mediated Drug Hypersensitivity. , 2007, , 380-390.		12
75	Cross-reactivity patterns of T cells specific for iodinated contrast media. Journal of Allergy and Clinical Immunology, 2007, 119, 1529-1536.	2.9	72
76	Predicting drug hypersensitivity by in vitro tests. ALTEX: Alternatives To Animal Experimentation, 2007, 24 Spec No, 49-52.	1.5	1
77	Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. Journal of Allergy and Clinical Immunology, 2006, 117, 455-462.	2.9	127
78	Activation of T cells by carbamazepine and carbamazepine metabolites. Journal of Allergy and Clinical Immunology, 2006, $118, 233-241$.	2.9	121
79	Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. International Journal of Dermatology, 2006, 45, 469-474.	1.0	65
80	Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS Journal, 2006, 8, E160-E165.	4.4	37
81	Pharmacological Interaction of Drugs with Immune Receptors: The p-i Concept. Allergology International, 2006, 55, 17-25.	3.3	189
82	Involvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 2919-2927.	6.1	129
83	In vitrotests of T cell-mediated drug hypersensitivity. Expert Review of Clinical Immunology, 2006, 2, 887-900.	3.0	11
84	Direct T-cell stimulations by drugs—bypassing the innate immune system. Toxicology, 2005, 209, 95-100.	4.2	60
85	T Cell-Regulated Neutrophilic Inflammation in Autoinflammatory Diseases. Journal of Immunology, 2005, 175, 7678-7686.	0.8	118
86	Lymphocyte Transformation Test. , 2005, , 405-408.		1
87	T cell–mediated reactions to iodinated contrast media: Evaluation by skin and lymphocyte activation tests. Journal of Allergy and Clinical Immunology, 2005, 115, 179-185.	2.9	132
88	The Drug Ambassador Project. Allergy and Clinical Immunology International, 2005, 17, 9-18.	0.3	11
89	Cytotoxic T Lymphocytes Derived from Patients with Chronic Hepatitis C Virus Infection Kill Bystander Cells via Fas-FasL Interaction. Journal of Virology, 2004, 78, 2152-2157.	3.4	50
90	Characterization of Human T Cells That Regulate Neutrophilic Skin Inflammation. Journal of Immunology, 2004, 173, 2151-2158.	0.8	154

#	Article	IF	Citations
91	A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology, 2004, 197, 47-56.	4.2	53
92	Cellular mechanisms of T cell mediated drug hypersensitivity. Current Opinion in Immunology, 2004, 16, 732-737.	5.5	59
93	Detection of specific IgE to quinolones. Journal of Allergy and Clinical Immunology, 2004, 113, 155-160.	2.9	135
94	Immune mechanism of drug hypersensitivity. Immunology and Allergy Clinics of North America, 2004, 24, 373-397.	1.9	74
95	A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine, 2004, 23, 58-68.	3.8	45
96	The immunological and clinical spectrum of delayed drug-induced exanthems. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 411-419.	2.3	75
97	Lessons from drug allergy: Against dogmata. Current Allergy and Asthma Reports, 2003, 3, 1-3.	5.3	16
98	Delayed Drug Hypersensitivity Reactions. Annals of Internal Medicine, 2003, 139, 683.	3.9	616
99	Characterization of drug-specific T cells in lamotrigine hypersensitivity. Journal of Allergy and Clinical Immunology, 2003, 111, 1393-1403.	2.9	198
100	Quinolone hypersensitivity. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 275-281.	2.3	48
101	Cross-reactivity with drugs at the T cell level. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 261-267.	2.3	31
102	Drug-induced autoimmunity. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 249-253.	2.3	34
103	Molecular Aspects of Drug Recognition by Specific T Cells. Current Drug Targets, 2003, 4, 1-11.	2.1	69
104	In vitro studies of core peptideâ€bearing immunopotentiating reconstituted influenza virosomes as a nonâ€live prototype vaccine against hepatitis C virus. International Immunology, 2002, 14, 615-626.	4.0	34
105	Covalent Binding of the Nitroso Metabolite of Sulfamethoxazole Leads to Toxicity and Major Histocompatibility Complex-Restricted Antigen Presentation. Molecular Pharmacology, 2002, 62, 628-637.	2.3	129
106	Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Current Opinion in Allergy and Clinical Immunology, 2002, 2, 301-305.	2.3	252
107	Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Current Opinion in Allergy and Clinical Immunology, 2002, 2, 325-331.	2.3	126
108	Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions. American Journal of Clinical Dermatology, 2002, 3, 229-238.	6.7	117

#	Article	IF	CITATIONS
109	Acute Generalized Exanthematous Pustulosis. American Journal of Pathology, 2002, 161, 2079-2086.	3.8	145
110	T cells in drug allergy. Current Allergy and Asthma Reports, 2002, 2, 9-15.	5.3	22
111	Deciphering the immune pathomechanism of cutaneous drug reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 34-36.	5.7	17
112	Modes of presentation of chemical neoantigens to the immune system. Toxicology, 2002, 181-182, 49-54.	4.2	27
113	Macular exanthema appearing 5Âdays after X-ray contrast medium administration. European Radiology, 2002, 12, S94-S97.	4.5	20
114	Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. Journal of Clinical Immunology, 2002, 22, 253-262.	3.8	13
115	Peptide vaccines against hepatitis B virus: from animal model to human studies. Molecular Immunology, 2001, 38, 457-465.	2.2	43
116	Perspectives: towards a peptide-based vaccine against hepatitis C virus. Molecular Immunology, 2001, 38, 475-484.	2.2	45
117	Immunohistology of drug-induced exanthema: clues to pathogenesis. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 299-303.	2.3	28
118	Predictive drug allergy testing: an alternative viewpoint. Toxicology, 2001, 158, 31-41.	4.2	35
119	Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. British Journal of Pharmacology, 2001, 132, 623-630.	5.4	88
120	Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. British Journal of Pharmacology, 2001, 133, 295-305.	5.4	115
121	Degeneracy and additional alloreactivity of drug-specific human $\hat{l}\pm\hat{l}^2+T$ cell clones. International Immunology, 2001, 13, 877-885.	4.0	59
122	Immunohistology of drug-induced exanthema: clues to pathogenesis. Current Opinion in Allergy and Clinical Immunology, 2001, 1 , 299-303.	2.3	13
123	T-cell involvement in drug-induced acute generalized exanthematous pustulosis. Journal of Clinical Investigation, 2001, 107, 1433-1441.	8.2	314
124	Virological and immunological characteristics of HIV treatment failure. Aids, 2000, 14, 1767-1774.	2.2	26
125	Human afferent lymph from normal skin contains an increased number of mainly memory / effector CD4+ T cells expressing activation, adhesion and co-stimulatory molecules. European Journal of Immunology, 2000, 30, 491-497.	2.9	65
126	T Cells Isolated from Positive Epicutaneous Test Reactions to Amoxicillin and Ceftriaxone are Drug Specific and Cytotoxic. Journal of Investigative Dermatology, 2000, 115, 647-652.	0.7	84

#	Article	IF	CITATIONS
127	Strong \hat{l} ± \hat{l} 2 and \hat{l} 3 \hat{l} 7TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia. Immunology Letters, 2000, 72, 75-82.	2.5	30
128	Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T Cells from Allergic Individuals. Journal of Immunology, 2000, 164, 6647-6654.	0.8	206
129	Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis. Journal of Allergy and Clinical Immunology, 2000, 106, 941-947.	2.9	27
130	Anaphylactic shock after subcutaneous injection of mandragora D3, a homeopathic drug. Journal of Allergy and Clinical Immunology, 2000, 106, 989-990.	2.9	10
131	Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. Journal of Allergy and Clinical Immunology, 2000, 106, 1171-1176.	2.9	118
132	Distinct Serum Cytokine Levels in Drug– and Measles–Induced Exanthema. International Archives of Allergy and Immunology, 1999, 120, 225-229.	2.1	52
133	Molecular Basis of Drug Recognition by Specific T–Cell Receptors. International Archives of Allergy and Immunology, 1999, 119, 173-180.	2.1	29
134	CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Immunology Letters, 1999, 65, 197-201.	2.5	27
135	Recognition of Local Anesthetics by $\hat{l}\pm\hat{l}^2+T$ Cells. Journal of Investigative Dermatology, 1999, 112, 197-204.	0.7	29
136	Chronic Idiopathic Urticaria: Natural Course and Association with Helicobacter pylori Infection. International Archives of Allergy and Immunology, 1999, 119, 60-63.	2.1	112
137	Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen⯆⯆⯆â¯: Journal of Allergy and Clinical Immunology, 1999, 104, 1239-1243.	2.9	53
138	Coprinus comatus (shaggy cap) is a potential source of aeroallergen that may provoke atopic dermatitis. Journal of Allergy and Clinical Immunology, 1999, 104, 836-841.	2.9	24
139	IgE-binding proliferative responses and skin test reactivity to Cop c 1, the first recombinant allergen from the basidiomycete Coprinus comatus. Journal of Allergy and Clinical Immunology, 1999, 104, 630-636.	2.9	30
140	HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. Aids, 1999, 13, 1857-1862.	2.2	101
141	Allergy to antibacterials: the problem with beta-lactams and sulfonamides. , 1998, 7, S23-S36.		0
142	Involvement of T cells in drug-induced allergies. Trends in Pharmacological Sciences, 1998, 19, 308-310.	8.7	29
143	Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. Aids, 1998, 12, 1341-1346.	2.2	19
144	High IL-5 Production by Human Drug-Specific T Cell Clones. International Archives of Allergy and Immunology, 1997, 113, 177-180.	2.1	63

#	Article	lF	Citations
145	Inhibition of syncytia-inducing (SI) virus by autologous serum from HIV-1-infected individuals. Clinical and Diagnostic Virology, 1996, 6, 127-135.	1.7	O
146	Anergy Induction in Human CD4+ T-Cell Clones by Stimulation with Soluble Peptides Does Not Require Cell Proliferation and Is Accompanied by Elevated IL4 Production. Cellular Immunology, 1996, 173, 79-86.	3.0	8
147	Involvement of CD80 in the generation of CD4+ cytotoxic T cells. Immunologic Research, 1996, 15, 126-140.	2.9	17
148	T cell recognition of penicillin G: Structural features determining antigenic specificity. European Journal of Immunology, 1996, 26, 42-48.	2.9	112
149	Noncytotoxic Human CD4+ T-Cell Clones Presenting and Simultaneously Responding to an Antigen Die of Apoptosis. Cellular Immunology, 1995, 161, 72-78.	3.0	25
150	Selective Expression of T-Cell Receptor-Vß in Acute Infectious Mononucleosis. Archives of Internal Medicine, 1995, 155, 1555.	3.8	3
151	T cells as antigen-presenting cells. Trends in Immunology, 1994, 15, 312-315.	7.5	103
152	Improved Sensitization of Antigen-Presenting Cells with Transferrin-Bound Peptides: Advantages in Competition for Antigen Presentation. Cellular Immunology, 1994, 158, 59-70.	3.0	9
153	A cell surface ELISA for the screening of monoclonal antibodies to antigens on viable cells in suspension. Journal of Immunological Methods, 1994, 171, 93-102.	1.4	26
154	The B7 adhesion molecule is expressed on activated human T cells: Functional involvement in Tâ€T cell interactions. European Journal of Immunology, 1993, 23, 2175-2180.	2.9	88
155	Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide. European Journal of Immunology, 1993, 23, 3217-3223.	2.9	23
156	Antigen-presenting human T cells and antigen-presenting B cells induce a similar cytokine profile in specific T cell clones. European Journal of Immunology, 1993, 23, 3350-3357.	2.9	35
157	Nonclassical Antigen-Presenting Cells Stimulate the Proliferation of ThO but not Th1/Th2 Clones and Modulate the Cytokine Pattern of T-Helper Clones. International Archives of Allergy and Immunology, 1992, 99, 370-372.	2.1	0
158	Use of antibody/peptide constructs to direct antigenic peptides to T cells: Evidence for T cell processing and presentation. Cellular Immunology, 1992, 139, 268-273.	3.0	20
159	Discrimination of human CD4 T cell clones based on their reactivity with antigen-presenting T cells. European Journal of Immunology, 1992, 22, 2295-2302.	2.9	25
160	Selective Stimulation of CD4 ⁺ Versus CD8 ⁺ T-Cell Subsets in Symptomatic and Asymptomatic HIV-1-Infected Individuals. AIDS Research and Human Retroviruses, 1991, 7, 773-780.	1.1	11
161	Dual antibody stimulation: Role of monocyte products and activation requirements of T cell subsets. Cellular Immunology, 1990, 125, 130-141.	3.0	3
162	Dichotomous effect of monocyte Fc receptor interaction on anti-CD3-induced immunoglobulin synthesis. Cellular Immunology, 1990, 126, 91-105.	3.0	4

#	Article	IF	CITATIONS
163	Lymphokine gene expression related to CD4 T cell subset (CD45R/CDw29) phenotype conversion. European Journal of Immunology, 1989, 19, 1569-1574.	2.9	49
164	Anti-CD4 antibody treatment of patients with rheumatoid arthritis: II. Effect of in vivo treatment on in vitro proliferative response of CD4 cells. Journal of Autoimmunity, 1989, 2, 643-649.	6.5	31
165	Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. Journal of Autoimmunity, 1989, 2, 627-642.	6.5	148
166	Anti-amiodarone antibodies: Detection and relationship to the development of side effects. American Journal of Medicine, 1988, 85, 197-202.	1.5	32
167	Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation. European Journal of Immunology, 1987, 17, 873-880.	2.9	66
168	T cell activation by cross-linking anti-CD3 antibodies with second anti-T cell antibodies: dual antibody cross-linking mimics physical monocyte interaction. European Journal of Immunology, 1987, 17, 1611-1618.	2.9	30
169	Differences of T-cell activation by the anti-CD3 antibodies Leu4 and BMA030. Cellular Immunology, 1987, 108, 175-187.	3.0	14
170	Different effects of IL-2 addition or antibody crosslinking on T-cell subset stimulation by CD3 antibodies. Cellular Immunology, 1986, 101, 195-203.	3.0	13
171	Characterization of T8 epitopes by enzymatic digestion, cross-blocking, and involvement in cell-mediated lympholysis. Cellular Immunology, 1985, 96, 398-408.	3.0	3
172	Si;½zary syndrome with hyposplenism. Blut, 1984, 49, 75-82.	1.2	1
173	In Vitro Functions of Human T Cells Expressing Fc-lgG or Fc-lgM Receptors. Immunological Reviews, 1981, 56, 163-198.	6.0	44
174	Fc receptors on human T lymphocytes. Cellular Immunology, 1979, 42, 410-417.	3.0	54